This is a working overview of prothymosin alpha, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-07. Anything still debated is marked as such rather than presented as settled.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Several factors accelerate degradation: alkaline pH, elevated temperature, exposure to oxidants, and the presence of residual moisture. Deamidation of asparagine residues and oxidation of methionine are the most commonly reported degradation routes. Because the peptide lacks disulfide bonds, it does not undergo the thiol-related aggregation seen in some other biologics, but physical aggregation can still occur at high concentration. Stability data are product-specific, and extrapolating shelf life between formulations is not reliable.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
The attenuator allows more time for the attenuator sequence domains to form loop structures, but does not produce a protein that is used in later tryptophan synthesis. Attenuation is a second mechanism of negative feedback in the trp operon. While the TrpR repressor decreases transcription by a factor of 70, attenuation can further decrease it by a factor of 10, thus allowing accumulated repression of about 700-fold. Attenuation is made possible by the fact that in prokaryotes (which have no nucleus), the ribosomes begin translating the mRNA while RNA polymerase is still transcribing the DNA sequence. This allows the process of translation to directly affect transcription of the operon. At the beginning of the transcribed genes of the trp operon is a sequence of 140 nucleotides termed the leader transcript (trpL). This transcript includes four short sequences designated 1–4. Sequence 1 is partially complementary to sequence 2, which is partially complementary to sequence 3, which is partially complementary to sequence 4. Thus, three distinct secondary structures (hairpins) can form: 1–2, 2–3 or 3–4. The hybridization of strands 1 and 2 to form the 1–2 structure prevents the formation of the 2–3 structure, while the formation of 2-3 prevents the formation of 3–4. The 3–4 structure is a transcription termination sequence, once it forms RNA polymerase will disassociate from the DNA and transcription of the structural genes of the operon will not occur. Part of the leader transcript codes for a short polypeptide of 14 amino acids, termed the leader peptide.
Amino acids are the precursors to proteins. They join by condensation reactions to form short polymer chains called peptides or longer chains called either polypeptides or proteins. These chains are linear and unbranched, with each amino acid residue within the chain attached to two neighboring amino acids. In nature, the process of making proteins encoded by RNA genetic material is called translation and involves the step-by-step addition of amino acids to a growing protein chain by a ribozyme that is called a ribosome. The order in which the amino acids are added is read through the genetic code from an mRNA template, which is an RNA derived from one of the organism's genes. There are 22 amino acids that get naturally incorporated into polypeptides; these are called proteinogenic amino acids or natural amino acids. Of these, 20 are encoded by the universal genetic code. The remaining 2, selenocysteine and pyrrolysine, are incorporated into proteins by unique synthetic mechanisms. Selenocysteine is incorporated when the mRNA being translated includes a SECIS element, which causes the UGA codon to encode selenocysteine instead of a stop codon. Pyrrolysine is used by some methanogenic archaea in enzymes that they use to produce methane. It is coded for with the codon UAG, which is normally a stop codon in other organisms.
The PFA-100 (Platelet Function Assay or Platelet Function Analyser) is a platelet function analyser that aspirates blood in vitro from a blood specimen into disposable test cartridges through a microscopic aperture cut into a biologically active membrane at the end of a capillary. The membrane of the cartridges are coated with collagen and adenosine diphosphate (ADP) or collagen and epinephrine inducing a platelet plug to form which closes the aperture. The PFA test result is dependent on platelet function, plasma von Willebrand Factor level, platelet number, and (to some extent) the hematocrit (that is, the percent composition of red blood cells in the sample). The PFA test is initially performed with the Collagen/Epinepherine membrane. A normal Col/Epi closure time (<180 seconds) excludes the presence of a significant platelet function defect. If the Col/Epi closure time is prolonged (>180 seconds), the Col/ADP test is automatically performed. If the Col/ADP result is normal (<120 seconds), aspirin-induced platelet dysfunction is most likely. Prolongation of both test results (Col/Epi >180 seconds, Col/ADP >120 seconds) may indicate the following;
=== Doubling time === The doubling time is the amount of time it would take for a breeder reactor to produce enough new fissile material to replace the original fuel and additionally produce an equivalent amount of fuel for another nuclear reactor. This was considered an important measure of breeder performance in early years, when uranium was thought to be scarce. However, since uranium is more abundant than thought in the early days of nuclear reactor development, and given the amount of plutonium available in spent reactor fuel, doubling time has become a less important metric in modern breeder-reactor design.
== Business == George Batten (1854–1918), advertising executive whose firm was part of the merger that created what is now BBDO Clarence Birdseye (1886–1956), inventor, entrepreneur and naturalist who is considered to be the founder of the modern frozen food industry John C. Bogle (1929–2019), founder and CEO of The Vanguard Group, a pioneer in financial investments John J. Cali (1918–2014), real estate developer Israel Crane (1774–1858), merchant J. Clydesdale Cushman (1887–1955), businessman who co-founded the real estate firm Cushman & Wakefield in 1917 Allen B. DuMont (1901–1965), television pioneer and inventor who created the DuMont Television Network Stephen Glasser (1943–2022), American publisher who founded the Legal Times Floyd Hall (born 1935), CEO of Kmart Charles B. Johnson (born 1933), businessman Ken Kurson (born 1968), political consultant, writer and journalist, who was editor-in-chief of The New York Observer between 2013 and 2017 Geraldine Laybourne (born 1947), former TV executive and entrepreneur, co-founder of Nickelodeon and Oxygen cable networks Benjamin Moore (1905–1917), co-founder with his brother Robert of Benjamin Moore & Co, in Brooklyn in 1883; lived in Upper Montclair Guy T. Viskniskki (1876–1949), newspaper editor and news executive who founded the World War I edition of the Stars and Stripes newspaper while serving as a U.S. Army officer in France with the American Expeditionary Force Bernard Wakefield (c. 1883–1967), British-American executive who co-founded the real estate firm Cushman & Wakefield in 1917
Sources: en.wikipedia.org
=== Background === Mogo is a sentient and living planet. When it is desired, its affiliation with the Corps is shown with foliage arranged into a green band, marked with the standard Green Lantern Corps lantern symbol, circling Mogo's equator. In its early appearances, Mogo is not a social Green Lantern and its interactions with the rest of the DC universe are not well documented. It avoids announcing its presence, preferring to represent itself using pseudonymous holograms. In Mogo's first appearance, it is explained that the planet-sized Mogo's gravitational field would wreak havoc on any other planet it would try to "visit", hence Mogo "doesn't socialize". At the same time, Mogo has allowed alien races to live on its surface and has been willing to change its conditions to suit them. When Parallax, possessing Hal Jordan, destroys the power battery on Oa and kills the Guardians, Mogo loses contact with the Green Lantern energy that helped sustain him. Without energy, Mogo loses consciousness and drifts through Sector 1014 until he is discovered by a nomadic alien race, who strip Mogo of his natural resources and pollute his environment. Mogo's body reacts instinctively, creating constructs to hinder the aliens' efforts to exploit his resources. Mogo is finally rescued by Kyle Rayner, who uses his power ring to reawaken him. With the restoration of the Green Lantern Corps, Mogo has taken on the role of a training and recreation planet for his fellow Green Lanterns. Soranik Natu, Kyle Rayner, and other Lanterns have traveled to his sector to ask for his counsel.
=== Hunger === Because patients are being fed intravenously, the subject does not physically eat, resulting in intense hunger pangs (pains). The brain uses signals from the mouth (taste and smell), the stomach and gastrointestinal tract (fullness) and blood (nutrient levels) to determine conscious feelings of hunger. In cases of TPN, the taste, smell and physical fullness requirements are not met, and so the patient experiences hunger, although the body is being fully nourished. Patients who eat food despite the inability can experience a wide range of complications, such as refeeding syndrome.
=== Others === A number of fusion proteins belong to none of the three main classes. Poxviruses employ a multiprotein system of 11 different genes and their relatives in the broader group of Nucleocytoviricota appear to do likewise. The structure of the fusion complex is not yet resolved. Scientists have produced some information on what each of the components bind to, but still not enough to produce a full picture. Hepadnaviridae, which includes the Hep B virus, uses different forms of the surface antigen (HBsAg - S, M and L) to fuse. It was found in 2021 that it has a fusion peptide in preS1, which is found in the L form.
== External links == Anatomy Atlases – Microscopic Anatomy, plate 10.198 Histology image: 10802loa – Histology Learning System at Boston University - "Digestive System: Alimentary Canal - esophagus " Histology image: 03301loa – Histology Learning System at Boston University - "Connective Tissue: lamina propria; loose connective tissue " UIUC Histology Subject 272 Anatomy photo: Digestive/mammal/system1/system3 - Comparative Organology at University of California, Davis - "Mammal, whole system (LM, Low)" Slide at ucla.edu
In a separate study of rehabilitative strength training following immobilization, creatine supplementation was associated with increased muscle MRF4 protein expression; however, whether changes in MRF4 directly mediate myonuclear accretion or hypertrophy remains uncertain.
Sources: en.wikipedia.org
The new state was organized as a federal monarchy; the emperor served as head of state and president of the federal compact, which comprised the allied constituent states—including Prussia, the three additional kingdoms (Bavaria, Saxony, and Württemberg), six grand duchies, five duchies, seven principalities, and the three republican free Hanseatic cities of Hamburg, Lübeck, and Bremen.
Hydrogen sulfide gas and the hydrosulfide anion are extremely toxic to mammals, due to their inhibition of the oxygen-carrying capacity of hemoglobin and certain cytochromes in a manner analogous to cyanide and azide (see below, under precautions).
Before the discovery of ribozymes, enzymes—which were defined [solely] as catalytic proteins—were the only known biological catalysts. In 1967, Carl Woese, Francis Crick, and Leslie Orgel were the first to suggest that RNA could act as a catalyst. This idea was based upon the discovery that RNA can form complex secondary structures. These ribozymes were found in the intron of an RNA transcript, which removed itself from the transcript, as well as in the RNA component of the RNase P complex, which is involved in the maturation of pre-tRNAs. In 1989, Thomas R. Cech and Sidney Altman shared the Nobel Prize in chemistry for their "discovery of catalytic properties of RNA". The term ribozyme was first introduced by Kelly Kruger et al. in a paper published in Cell in 1982. It had been a firmly established belief in biology that catalysis was reserved for proteins. However, the idea of RNA catalysis is motivated in part by the old question regarding the origin of life: Which comes first, enzymes that do the work of the cell or nucleic acids that carry the information required to produce the enzymes? The concept of "ribonucleic acids as catalysts" circumvents this problem. RNA, in essence, can be both the chicken and the egg. In the 1980s, Thomas Cech, at the University of Colorado Boulder, was studying the excision of introns in a ribosomal RNA gene in Tetrahymena thermophila. While trying to purify the enzyme responsible for the splicing reaction, he found that the intron could be spliced out in the absence of any added cell extract.
In 1998, he voted for a bill that would have increased minimum sentencing for possessing a gun while committing a federal crime to ten years in prison, including nonviolent crimes such as marijuana possession. In 2005, Sanders voted for the Protection of Lawful Commerce in Arms Act. The purpose of the act was to prevent firearms manufacturers and dealers from being held liable for negligence when crimes have been committed with their products. As of 2016, he said that he has since changed his position and would vote for legislation to defeat this bill.
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.